Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Payables: 2012-2025

Historic Payables for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $1.9 million.

  • Enanta Pharmaceuticals' Payables fell 75.66% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year decrease of 56.87%. This contributed to the annual value of $1.9 million for FY2025, which is 75.66% down from last year.
  • As of FY2025, Enanta Pharmaceuticals' Payables stood at $1.9 million, which was down 75.66% from $8.0 million recorded in FY2024.
  • Enanta Pharmaceuticals' Payables' 5-year high stood at $9.5 million during FY2021, with a 5-year trough of $1.9 million in FY2025.
  • In the last 3 years, Enanta Pharmaceuticals' Payables had a median value of $4.1 million in 2023 and averaged $4.7 million.
  • Its Payables has fluctuated over the past 5 years, first surged by 95.31% in 2024, then slumped by 75.66% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Payables (Yearly) stood at $9.5 million in 2021, then plummeted by 37.11% to $6.0 million in 2022, then slumped by 31.72% to $4.1 million in 2023, then skyrocketed by 95.31% to $8.0 million in 2024, then crashed by 75.66% to $1.9 million in 2025.